Pdt Partners, LLC Prothena Corp Public LTD CO Transaction History

Pdt Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $186,126 - $323,809	-4,420 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $213,044 - $348,693	4,420 New	4,420 $315,000
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $387,270 - $525,330	-39,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$9.56 - $12.51 $167,300 - $218,925	17,500 Added 81.4%	39,000 $408,000
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $118,842 - $270,254	-15,888 Reduced 42.49%	21,500 $340,000

Q3 2019 Nov 14, 2019	SELL	$6.89 - $10.45 $126,879 - $192,436	-18,415 Reduced 33.0%	37,388 $293,000
Q2 2019 Aug 14, 2019	SELL	$8.85 - $12.49 $27,435 - $38,719	-3,100 Reduced 5.26%	55,803 $590,000
Q1 2019 May 15, 2019	BUY	$10.32 - $14.49 $607,878 - $853,504	58,903 New	58,903 $714,000

186

45.4M

119K

144K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $957M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.